UGenome provides bioinformatics software tools, MAXX and ProPEx, for somatic variant detection and pharmacogenomic analysis to enhance medication response. The platform delivers clinically actionable insights that improve treatment options for patients by personalizing genomic medicine.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for determining medication response rely on population-level data from clinical trials, which do not account for individual genetic variability, leading to ineffective treatments or adverse side effects for some patients. Traditional genetic testing assesses disease risk but often overlooks how a patient's body will metabolize specific medications.
Solution
UGenome offers bioinformatics software, including MAXX and ProPEx, that analyzes a patient's entire genome to predict individual responses to medications. By leveraging whole genome sequencing, the platform identifies how a person's body metabolizes a particular medication, its potential efficacy, and possible side effects. This comprehensive approach enables clinicians to personalize treatment plans, optimize dosing, and select alternative medications based on a patient's unique pharmacogenomic profile, ultimately improving health outcomes.
Target Audience
UGenome's primary audience includes healthcare professionals, such as clinicians and geneticists, seeking to leverage genomic data for personalized medicine, as well as pharmaceutical companies in therapeutic development.
Features
- MAXX and ProPEx tools for somatic variant detection and medication response analysis
- Whole genome sequencing analysis to predict individual medication responses
- Identification of potential medication efficacy and side effects based on a patient's genetic makeup
- Clinical decision support with targeted recommendations for personalized treatment
- Dosing recommendations based on pharmacogenomic profiles
- Alternative medication suggestions if a drug is unsuitable based on pharmacogenomics